Show simple item record

dc.contributor.authorChantada, Guillermo L
dc.contributor.authorQaddoumi, Ibrahim
dc.contributor.authorCanturk, Serife
dc.contributor.authorKhetan, Vikas
dc.contributor.authorMa, Zhigui
dc.contributor.authorKimani, Kahaki
dc.contributor.authorYeniad, Baris
dc.contributor.authorSultan, Iyad
dc.contributor.authorSitorus, Rita S
dc.contributor.authorTacyildiz, Nurdan
dc.contributor.authorAbramson, David H
dc.date.accessioned2013-08-05T11:16:49Z
dc.date.available2013-08-05T11:16:49Z
dc.date.issued2011-03
dc.identifier.citationPediatric Blood & Cancer Volume 56, Issue 3, pages 341–348, March 2011en
dc.identifier.urihttp://onlinelibrary.wiley.com/doi/10.1002/pbc.22843/full
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/54388
dc.description.abstractSurvival of retinoblastoma is >90% in developed countries but there are significant differences with developing countries in stage at presentation, available treatment options, family compliance, and survival. In low-income countries (LICs), children present with advanced disease, and the reasons are socioeconomic and cultural. In middle-income countries (MICs), survival rates are better (>70%), but there is a high prevalence of microscopically disseminated extraocular disease. Programs for eye preservation have been developed, but toxicity-related mortality is higher. Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence.en
dc.language.isoenen
dc.publisherUniversity of Nairobien
dc.titleStrategies to Manage Retinoplastoma in Developing Countriesen
dc.typeArticleen
local.publisherFaculty of medicineen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record